[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. [2] Kamisawa T, Wood LD, Itoi T, et al.Pancreatic cancer[J]. Lancet, 2016, 388(10039):73-85. [3] Mohammed A, Janakiram NB, Madka V, et al.Current challenges and opportunities for chemoprevention of pancreatic cancer[J]. Curr Med Chem, 2018, 25(22):2535-2544. [4] Tsai S, Evans DB.Therapeutic advances in localized pancreatic cancer[J]. JAMA Surg, 2016, 151(9):862-868. [5] Neoptolemos JP, Kleeff J, Michl P, et al.Therapeutic developments in pancreatic cancer: current and future perspectives[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6):333-348. [6] Cho SY, Kang W, Han JY, et al.An integrative approach to precision cancer medicine using patient-derived xenografts[J]. Mol Cells, 2016, 39(2):77-86. [7] Zhang YJ, Wen CL, Qin YX, et al.Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance[J]. Oncol Rep, 2017, 38(6):3335-3346. [8] Guan Z, Lan H, Sun D, et al.A potential novel therapy for FGFR1-amplified pancreatic cancer with bone metastasis, screened by nextgeneration sequencing and a patient derived xenograft model[J]. Oncol Lett, 2019, 17(2):2303-2307. [9] Guan Z, Lan H, Chen X, et al.Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis[J]. Mol Med Rep, 2017, 16(4):4784-4790. [10] Dai W, Liu J, Li Q, et al.A comparison of next-generation sequencing analysis methods for cancer xenograft samples[J]. J Genet Genomics, 2018, 45(7):345-350. [11] 张贺, 张彩勤, 赵勇, 等. 胰腺癌患者临床特征与异种移植模型的相关性[J]. 实验动物科学, 2018, 35(3):46-51. [12] Lipner MB, Marayati R, Deng YM, et al.Metformin treatment does not inhibit growth of pancreatic cancer patient-derived xenografts[J]. PLoS One, 2016, 11(1):e014711311. [13] Xiang J, Hu Q, Qin Y, et al.TCF7L2 positively regulates aerobic glycolysis via the EGLN2 /HIF-1α axis and indicates prognosis in pancreatic cancer[J]. Cell Death Dis, 2018, 9(3):321. [14] 胡斌权, 陈城明, 张同弟, 等. 人体肿瘤PDX移植模型的优与劣[J]. 实验动物科学, 2015, 32(5):59-62. [15] Hernandez MC, Bergquist JR, Leiting JL, et al.Patient-derived xenografts can be reliably generated from patient clinical biopsy specimens[J]. J Gastrointest Surg,2019, 23(4):818-824. [16] Allaway RJ, Fischer DA, de Abreu FB, et al. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites[J]. Oncotarget, 2016, 7(13):17087-17102. [17] 张贺, 陈薛, 张彩勤, 等. 基于胰腺癌患者来源异种移植模型的化疗药物筛选[J]. 中国实验动物学报, 2018, 26(1):29-35. [18] Gambara G, Gaebler M, Keilholz U, et al.From chemotherapy to combined targeted therapeutics: in vitro and in vivo models to decipher intra-tumor heterogeneity[J]. Front Pharmacol, 2018, 9(77):1-18. [19] Sereti E, Karaqianellou T, Kotsoni L, et al.Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?[J]. J Proteomics, 2018, 30(118):107-118. [20] Hiroshima Y, Zhang Y, Zhang N, et al.Patient-derived orthotopic xenograft (PDOX) nude mouse model of soft-tissue sarcoma more closely mimics the patient behavior in contrast to the subcutaneous ectopic model[J]. Anticancer Res, 2015, 35(2):697-701. [21] 师长宏. 肿瘤患者来源的异种移植(PDX)模型[J]. 实验动物与比较医学, 2018, 38(3):165-168. [22] Hino A, Yoshida H, Tada Y, et al.Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia[J]. Int J Hematol, 2016, 104(5):605-611. [23] Witkiewicz AK, Balaji U, Eslinger C, et al.Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer[J]. Cell Rep, 2016, 16(7):2017-2031. [24] Liu X, Meltzer SJ.Gastric cancer in the era of precision medicine[J]. Cell Mol Gastroenterol Hepatology, 2017, 3(3):348-358. [25] 卓萌, 焦锋, 王理伟, 等. 胰腺癌微环境治疗策略的进展与思考[J]. 中国肿瘤临床, 2018, 45(6):271-276. [26] Li X, Lee Y, Kang Y, et al.Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma[J]. Cell Death Differ, 2019, 26(2):382-393. [27] Li X, Truty MA, Kang Y, et al.Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery[J]. Clin Cancer Res, 2014, 20(24):6529-6540. [28] Brown CE, Alizadeh D, Starr R, et al.Regression of glioblastoma after chimeric antigen receptor T cell therapy[J]. N Engl J Med, 2016, 375(26):2561-2569. [29] Jiang H, Song B, Wang P, et al.Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells[J]. Protein Cell, 2017, 8(12):926-931. [30] Cao R, Song W, Ye C, et al.Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer[J]. Cancer Med, 2019, 8(2):643-655. [31] Gerber MH, Underwood PW, Judge SM, et al.Local and systemic cytokine profiling for pancreatic ductal adenocarcinoma to study cancer cachexia in an era of precision medicine[J]. Int J Mol Sci, 2018, 19(12):1-14. [32] Chernenko E, Meir J, Bedi A, et al.Patient-derived xenografts as tools in pharmaceutical development[J]. Clin Pharmacol Ther, 2016, 99(6):612-621. [33] 刘宏飞, 陈晓红, 黄志刚, 等. 类器官和人源性肿瘤组织异种移植模型在肿瘤研究中的应用[J]. 中国比较医学杂志, 2019, 29(3):103-108. [34] Moreira L, Bakir B, Chatterji P, et al.Pancreas 3D organoids:current and future aspects as a research platform for personalized medicine in pancreatic cancer[J]. Cell Mol Gastroenterol Hepatol, 2018, 5(3):289-298. [35] Perales-Pat n J, Pi eiro-Ya ez E, Tejero H, et al. Pancreas cancer precision treatment using avatar mice from a bioinformatics perspective[J]. Public Health Genomics, 2017, 20(2):81-91. [36] Prasad V.Perspective:The precision-oncology illusion[J].Nature, 2016, 537(7619):S63. [37] Tannock IF, Hickman JA.Limits to personalized cancer medicine[J]. N Engl J Med, 2016, 375(13):1289-1294. [38] 胡斌权, 曹博, 师长宏. 胃癌人源性异种移植模型制备中的问题与策略[J]. 中国实验动物学报, 2017, 25(6):643-647. |